Crossmark

Efficacy and safety of human soluble thrombomodulin (ART-123) for treatment of patients in France with sepsis-associated coagulopathy: post hoc analysis of SCARLET

Crossref DOI link: https://doi.org/10.1186/s13613-021-00842-4

Published Print: 2021

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

FranÃ§ois, Bruno https://orcid.org/0000-0002-2531-1652
Fiancette, Maud

Helms, Julie

Mercier, Emmanuelle

Lascarrou, Jean-Baptiste

Kayanoki, Toshihiko

Tanaka, Kosuke

Fineberg, David

Vincent, Jean-Louis

Wittebole, Xavier
Funding

Funding for this research was provided by:

Asahi Kasei Pharma Corporation

Asahi Kasei Pharma America Corporation
License Information

Text and Data Mining valid from 2021-01-01

Text and Data Mining valid from 2021-01-01

Version of Record valid from 2025-11-19
More Information

This article is maintained by: Elsevier

Article Title: Efficacy and safety of human soluble thrombomodulin (ART-123) for treatment of patients in France with sepsis-associated coagulopathy: post hoc analysis of SCARLET

Journal Title: Annals of Intensive Care

CrossRef DOI link to publisher maintained version: https://doi.org/10.1186/s13613-021-00842-4

Content Type: article

Copyright: Copyright Â© 2021 The Author(s) 2021. Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below